Sulindac metabolites decrease cerebrovascular malformations in CCM3-knockout mice
Luca Bravi, Noemi Rudini, Roberto Cuttano, Costanza Giampietro, Luigi Maddaluno, Luca Ferrarini, Ralf H Adams, Monica Corada, Gwenola Boulday, Elizabeth Tournier-Lasserve, Elisabetta Dejana, Maria Grazia Lampugnani, Luca Bravi, Noemi Rudini, Roberto Cuttano, Costanza Giampietro, Luigi Maddaluno, Luca Ferrarini, Ralf H Adams, Monica Corada, Gwenola Boulday, Elizabeth Tournier-Lasserve, Elisabetta Dejana, Maria Grazia Lampugnani
Abstract
Cerebral cavernous malformation (CCM) is a disease of the central nervous system causing hemorrhage-prone multiple lumen vascular malformations and very severe neurological consequences. At present, the only recommended treatment of CCM is surgical. Because surgery is often not applicable, pharmacological treatment would be highly desirable. We describe here a murine model of the disease that develops after endothelial-cell-selective ablation of the CCM3 gene. We report an early, cell-autonomous, Wnt-receptor-independent stimulation of β-catenin transcription activity in CCM3-deficient endothelial cells both in vitro and in vivo and a triggering of a β-catenin-driven transcription program that leads to endothelial-to-mesenchymal transition. TGF-β/BMP signaling is then required for the progression of the disease. We also found that the anti-inflammatory drugs sulindac sulfide and sulindac sulfone, which attenuate β-catenin transcription activity, reduce vascular malformations in endothelial CCM3-deficient mice. This study opens previously unidentified perspectives for an effective pharmacological therapy of intracranial vascular cavernomas.
Keywords: cerebral cavernous malformation; endothelial cells; sulindac metabolites; vascular pathology; β-catenin.
Conflict of interest statement
The authors declare no conflict of interest.
Figures





Source: PubMed
Prochains essais cliniques
-
NCT07948928RecrutementDiabète sucré, Type 2 | Diabète sucré
-
NCT07937228Recrutement
-
NCT07882173Pas encore de recrutement
-
NCT07902921Pas encore de recrutementCancer du poumon non à petites cellules | NSCLC | Cancer du poumon | Cancer de la prostate | CPRCm | Cancer de la prostate métastatique résistant à la castration | Tumeurs épithéliales thymiques | TETs | Thymic Carcinomas | Thymomas
-
NCT07882160RecrutementAcides gras, Oméga-3 | Huiles de poisson
-
NCT07853781Recrutement
-
NCT07859800Pas encore de recrutement
-
NCT07828613Pas encore de recrutementFracture ouverte du tibia | Fracture de l'extrémité inférieure | Luxation ouverte de la cheville | Blessures aux extrémités inférieures
-
NCT07796373Pas encore de recrutementLa leucémie lymphocytaire chronique | Petite leucémie lymphoïde
-
NCT07768215Pas encore de recrutementMort cérébrale | Respiration artificielle
-
NCT07764536RecrutementTrouble déficitaire de l'attention/hyperactivité | Trouble des conduites | Trouble oppositionnel avec provocation | Troubles du comportement perturbateur
-
NCT07756840Pas encore de recrutementMaladies laryngées | Maladies trachéales | Virus du papillome humain (VPH) | Infection à papillomavirus | Tumeur des voies respiratoires | Respiratory Recurrent Papillomatosis (RRP)